You “Should Have Seen It Coming”: European Payers Speak out on the Evolving Oncology Reimbursement Landscape

Share Article

eyeforpharma, London: Payers from some of Europe’s key healthcare markets offer guidance for pharmaceutical companies struggling to respond to evolving reimbursement practices.

News Image
I’m always amazed when companies have a new oncology product and demonstrate more additional months of life and forget to look at quality of life.

Speaking to eyeforpharma, payers from Germany, Spain and the United Kingdom have offered an olive branch of assistance to pharmaceutical firms who are currently struggling to keep up with the pace of an evolving reimbursement landscape in a difficult economic climate.

Wolfgang Kaesbach, formerly Head of the Pharmaceutical Department at GKV Spitzenverband, spoke to eyeforpharma about the slow response to AMNOG legislation from the industry, saying, “In Germany, we actually introduced a value assessment in 2004 and renewed it in AMNOG. I wonder why pharma-ceutical companies didn’t learn in 2004 that this was where we are going with respect to mortality and morbidity. I wonder why pharmaceutical companies had neglected to prepare in 2004 and now they act like everything has changed, that they have not prepared for this situation and they should have seen it coming.”

“[You need to] present reliable data and evidence to the committee on mortality, morbidity and quality of life. I’m always amazed when companies have a new oncology product and demonstrate more additional months of life and forget to look at quality of life.”

The insights, which were published in eyeforpharma’s recent Oncology Reimbursement white paper, echo similar sentiments from Spain and the UK.

The white paper, published by eyeforpharma and featuring the opinions of key payers and experts in the UK, Germany and Spain, goes on to examine the drivers behind evolving attitudes towards oncology reimbursement. Contributing to the research, former head of GKV-Spitzenverband Wolfgang Kaesbach rebukes the assertion that value-based pricing is a great complication for German oncology products. “In Germany, we actually introduced a value assessment in 2004 and renewed it in AMNOG. I wonder why pharmaceutical companies didn’t learn in 2004 that this was where we are going with respect to mortality and morbidity.”

Similarly, Mark Wilkinson of the new NHS Barnsley Clinical Commissioning Group points to the impact of lobby groups within oncology as “a likely factor that will push back against any tightening of assessment criteria for innovative products” in the UK.

This research comes ahead of eyeforpharma’s Oncology Market Access Europe summit in November 2013 in Berlin. Payer perceptions of oncology value propositions will be at the top of the agenda as attendees discuss strategies for market access in a changing environment.

To download a free copy of the research in full, visit the event website or contact Aidan Brain on the details below:

Aidan Brain
Head of Oncology
eyeforpharma
abrain(at)eyeforpharma(dot)com
(+44)0207 375 7513

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ben Swanson
eyeforpharma
020 7375 7519
Email >
Follow us on
Visit website